Lifespan Vision Ventures Invests in Paulex Bio
- LifeSpan Vision Ventures
- Dec 31, 2025
- 2 min read
Norwalk, CT – November 24, 2025 - Lifespan Vision Ventures, an investment firm focused on therapeutics that improve human healthspan, today announced an investment in Paulex Bio as part of MDB Capital’s $16.8 million private placement, supporting the company’s development of a first-in-class oral therapy aimed at restoring the body’s ability to produce its own insulin.
Paulex Bio is pioneering an oral regenerative medicine designed to help the pancreas rebuild insulin-producing cells. This approach seeks to address the underlying cause of both Type 1 and Type 2 diabetes, moving beyond symptom management toward the potential for a disease-modifying treatment. The company’s leadership team brings a proven track record of advancing the only disease-modifying preventative Type 1 Diabetes treatment, leading to a successful acquisition.
Andrew Worden, Founding Partner at Lifespan Vision Ventures said, “Our mission is to back therapies that meaningfully improve human healthspan. Paulex Bio’s work represents a bold step toward restoring metabolic function rather than managing decline. The prospect of a simple oral therapy that helps the body regain its natural ability to produce insulin has profound implications and we are excited to support the Paulex team as they advance this groundbreaking approach.”
About Paulex Bio
Paulex Bio is developing oral medicines to regenerate pancreatic islet beta-cells and restore normal insulin production.
About MDB Capital
MDB Capital is a venture-focused investment bank specializing in building IP-driven companies from inception. We partner with founders to define strategy, secure foundational intellectual property, structure early financings, and accelerate the path from scientific discovery to public markets. Guided by our Public Venture model, we focus on financing the emerging leaders in each technology domain we enter.
About Lifespan Vision Ventures
Lifespan Vision Ventures is a forward-thinking venture capital firm specializing in investments within the aging and longevity space.
Contact: info@lifespanvision.com
